DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

**Time and Date:** 11 a.m.–5 p.m., March 31, 2010 (Closed).

**Place:** Teleconference.

**Status:** The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

**Matters To Be Discussed:** The meeting will include the initial review, discussion, and evaluation of applications received in response to “TRIAD Legacy Study, FOA DP 10–005.”

**Contact Person for More Information:** Don Blackman, PhD, Scientific Review Officer, National Center for Chronic Disease and Health Promotion, Office of the Director, Extramural Research Program Office, 4770 Buford Highway, NE., Mailstop K–92, Atlanta, GA 30341, telephone: (770) 488–3023, e-mail: DBlackman@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.


Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2010–3047 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0001]

Pediatric Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

**Name of Committee:** Pediatric Advisory Committee.

**General Function of the Committee:** To provide advice and recommendations to the agency on FDA’s regulatory issues.

**Date and Time:** The meeting will be held on Monday, March 22, 2010, from 8 a.m. to 6 p.m.

**Location:** Bethesda Marriott Hotel, 5151 Pooks Hill Rd., Bethesda, MD., 20814.

**Contact Person:** Doreen Kezer, Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane (HF–33), rm. 14–65, Rockville, MD 20857, 301–827–1249, e-mail: Doreen.Kezer@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 8732310001. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

**Agenda:** The Pediatric Advisory Committee will meet to discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, for: Anthelios 40, Cardiolite (technetium Tc-99), Nasacort AQ (triamcinolone), Viramune